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There is a regular improvement in the early clinical disclosure of various 
atypical melanocytic neoplasms (AMN). The histopathological examination 
of AMN remains mandatory for establishing their diagnosis and proper 
management. Panels of experts in AMN diagnosis report only moderate 
agreement in a diversity of puzzling cases. Some AMN have been differently 
designated in the literature including atypical Spitz tumor, metastasizing Spitz 
tumor, borderline and intermediate melanocytic tumor, malignant Spitz nevus 
and pigmented epithelioid melanocytoma or animal-type melanoma. Some 
acronyms have been further offered such as MELTUMP (after “melanocytic 
tumor of uncertain malignant potential”) and STUMP (after “Spitzoid 
melanocytic tumor of uncertain malignant potential”). In this review, such 
AMN at the exclusion of cutaneous malignant melanoma (MM) variants, are 
grouped under the tentative broad heading cutaneous melanocytoma. These 
lesions typically follow an indolent course, although they exhibit an atypical and 
sometimes worrisome patterns or cytologic aspects. Rare cases of cutaneous 
melanocytomas progress to locoregional clusters of lesions (agminate lesions), 
and even to regional lymph nodes. At times, the distinction between a cutaneous 
melanocytoma and MM remains problematic and even proves to be merely 
impossible. However, multipronged immunohistochemistry helps assessing the 
malignancy risk.
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Although conventional histology is the mainstay for diagnosing 
AMN, clinical features, in particular the dermoscopic aspects 
remain of central importance. Cutaneous melanocytoma in its strict 
etymological sense, refers to benign tumor of melanocytes [10,19]. 
This term encompasses melanocytic neoplasms which do not meet 
the regular histological criteria of any specific type of common 
melanocytic naevi and SCMM [15,19]. They often develop singly, 
but occasionally, multiple cutaneous melanocytomas occur. Some 
of these lie grouped together (agminate type) and potentially recur 
after removal of a solitary lesion [14,21]. The term melanocytoma is 
similarly used in other fields of human pathology (leptomeninges, 
eye) and animal pathology (skin) for distinguishing peculiar and 
usually benign melanocytic neoplasms [22-24].
The recognition of intermediate sets of AMN and a better 
molecular staging of SCMM types has benefited from progresses 
in immunohistochemistry [25,26]. Using such an approach, most 
uncommon SCMM variants are identified with confidence [9,12,13]. 
It is acknowledged that SCMM molecular alterations and their 
respective immunological responses accompany the neoplastic 
progression from incipient to advanced stages. In this field, it is 
possible to use markers of proliferation, melanocytic differentiation 
and immunomodulation. In addition, the identification of signalling 
molecules, nerve growth factors and receptors is potentially useful, 
particularly in spindle cell variants of SCMM.
Triggered melanocytic naevi and cutaneous 
melanocytomas
In a series of endogenous and exogenous conditions, 
Introduction
Over the past decades, the worldwide incidence of sporadic 
cutaneous malignant melanoma (SCMM) has considerably increased 
in Caucasian populations [1-4]. In this perspective, there is growing 
need to improve diagnostic procedures supporting early treatment 
and decreasing SCMM morbidity and mortality.
SCMM are in part classified according to its clinical growth rate. 
Fast-growing SCMM are typically characterized by a vertical growth 
pattern. They have a worse prognosis compared to slow-growing 
SCMM which are commonly confined superficially [5,6].
In most instances, the histopathological presentation of SCMM 
is straightforward for experts in the field [7]. SCMM are classified 
according to the total thickness of the primary tumor, the proliferative 
activity, the presence of ulceration, the tissue level of penetration 
depth, and the identification of metastases. However, due to the 
wide spectrum of histological features the situation occasionally 
appears ambiguous [8,9]. For instance, in small size melanocytic 
lesions, all the classical histological criteria for borderline SCMM 
or undisputable SCMM are not always met, or they fail to make the 
distinction confidently. Those neoplasms are tentatively classified in 
a spectrum of atypical melanocytic neoplasms (AMN) encompassing 
intermediate categories [10-19] variously referred to as cutaneous 
melanocytomas, melanocytic dysplasia’s, minimal deviation 
melanomas, borderline melanomas, melanocytic tumors of uncertain 
malignant potential (MELTUMP) and spitzoid melanocytic tumors 
of uncertain malignant potential (STUMP) [20].
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melanocytic naevi are triggered and some of them appear as 
cutaneous melanocytomas. A set of specific internal messages and 
environmental factors have been identified in this field. Examples are 
cutaneous melanocytomas developed on congenital nevi, dysplastic 
nevi [27], nevi modified by pregnancy or hormonal contraception 
[28], nevi of subjects on growth hormone therapy [11], nevi under 
ultraviolet-light irradiation [29,30]. It should be mentioned that some 
of these lesions mimick SCMM or are at risk for MM development. 
The possibility of a cutaneous melanocytoma should be evoked in 
each single case. In this review, the term cutaneous melanocytoma 
encompasses a broad category of melanocytic neoplasms that are 
further distinguished according to the identified origins and the 
clinico-pathological confrontation.
Globally, the cutaneous melanocytoma class is histologically 
recognized by the combination of some criteria including architectural 
disorganisation and asymmetry, discrete nuclear atypia and 
anisokaryocytosis, as well as the eventual juxtaposition of an ancillary 
focal or diffuse inflammatory cell reaction. However, the variable 
combination and extent of such signs in different lesions preclude 
establishing any straightforward set of major criteria identifying 
distinct specific subsets of cutaneous melanocytomas, with, however, 
the exception of the common type of Spitz melanocytoma (nevus).
Another special type of cutaneous melanocytoma presents as an 
atypical dermal nodule in an otherwise normal-looking melanocytic 
nevus. Such atypical nodules suggest an intralesional transformation 
recognized by some pathologists as a sign of malignancy, although it 
does not exhibit other features of aggressive behavior. The increase 
in size of this type of melanocytic lesion is mainly due to more 
abundant, pale cytoplasm in each individual cell. The nuclei show 
only a marginal increase in size and do not exhibit pleomorphism. 
Invagination of the nucleus by cytoplasm possibly occurs, giving a 
vacuolated appearance. Mitoses are hardly ever seen.
After excluding the pregnancy-related changes in melanocytic 
lesions, the overall cutaneous melanocytoma gender ratio (F/M) 
is about 1.6 [19]. The age distribution is similar in the both gender 
groups. The prevalence of all melanocytomas peaks during the 3rd 
and 4th decades of life and a sharp decrease occurs after the age of 50 
years on. Such age and gender distributions resemble that of SCMM 
[15].
The distinction between cutaneous melanocytomas and SCMM 
ideally expects that all members of each group behave either 
completely benign or fully malignant. This concept probably does not 
fully hold true. The variability in the histopathological presentations 
of SCMM and cutaneous melanocytomas poses diagnostic difficulties 
and the clinical attributes occasionally remain disturbing. Any error 
in this differential diagnosis has profound consequences including 
mutilating overtreatment or, conversely, life-threatening under 
treatment. At the present time, controversies exist as to the diagnoses 
to be given for certain neoplasms and their predictive evolution 
leading to potential implication in legal liability.
Microscopic presentation of cutaneous melanocytomas
The distinction between cutaneous melanocytomas and SCMM 
presupposes that all members of each group are either completely 
benign or fully malignant. Such a concept probably does not hold 
true. The histopathological variability of cutaneous melanocytomas 
implements diagnostic difficulties, particularly in the distinction 
with SCMM. In some instances, the clinical aspects are similarly 
disturbing. Distinguishing, on the one hand, SCMM including its 
unusual variants masquerading as other entities and, on the other 
hand, benign lesions mimicking SCMM is one of the thorniest 
diagnostic conundrums. A mistake in this differential diagnosis leads 
to profound consequences including mutilating overtreatment or 
conversely life threatening under treatment. At present, controversies 
exist as to the diagnoses given to some neoplasms and their predictive 
evolution. As a result, there is potential implication in legal liability.
A consensus clearly exists regarding the inadequacy of some 
current clinico-pathologic classifications and the need for additional 
research in this area. Any empiric statement and dogmatic opinion 
in the fields as to the nosology of several types of cutaneous 
melanocytomas seem to vary widely. Even the definition of 
malignancy is disputed in the field of AMN. Some AMN, particularly 
those with an atypical spitzoid aspect, do not remain confined to the 
primary site. They exhibit the propensity to spread regionally in the 
skin (agminate type) and possibly to the regional lymph nodes [17], 
but not to further distant sites. The survival rate appears unaffected by 
such regional progression.
The interpretation of regional spread is subject to controversy. 
Some authors regard it as a formal proof of malignancy considering the 
secondary lesions as satellitosis or in-transit metastases. By contrast, 
others argue that this stance constitutes an overinterpretation. 
Nonetheless, any regional cutaneous and nodal spread of cutaneous 
melanocytomas is not similar to distant metastasis to internal organs 
and does not constitute a definitive proof of malignancy.
For a series of AMN, the current histopathologic criteria for 
benignancy or malignancy are not fully met or fail to make the 
distinction between these two basic conditions with confidence. Some 
differentiation markers are routinely used when facing an atypical 
melanocytic neoplasm. Immunohistochemistry is used as an adjunct 
for distinguishing SCMM and cutaneous melanocytomas or other 
neoplasms. The common antibodies are directed to the S100 protein, 
the gp100/HMB45, the melan A/MART-1, the CD63/NKi-C3 and 
tyrosinase [31].
In general, the common benign melanocytic neoplasms are 
structured in an orderly manner showing symmetry and so-called 
maturation with deeper location of smaller cells toward the base of 
the lesion. In general, the sensitivity of the differentiation markers 
decreases or becomes heterogeneous in SCMM with increasing 
clinical stage including metastatic lesions [32]. Such a feature is not 
found with maturation of cutaneous melanocytomas. It should be 
mentioned that immunohistochemistry proved to be very useful in 
tracking SCMM microsatellites [33] which are predictors of sentinel 
lymph node metastases and relapse-free survival [34].
Growth fraction, proliferation and apoptosis in cutaneous 
melanocytomas
The disturbance of autonomous growth regulatory pathways 
in melanocytomas and SCMM appears to be of prime importance. 
Atypical tripolar mitotic figures were indicative for SCMM 
rather than cutaneous melanocytomas. Autoradiography after 
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incorporation of tritiated thymidine [33] revealed a positive 
correlation between the 3H-TdR labeling index and the SCMM 
thickness. Metastases remained with a high immunolabeling index 
while benign melanocytic lesions showed a very low proportion 
of cells in S phase. As the radioautography procedure was almost 
impossible to apply routinely, the method was switched to the Ki67 
immunolabelings which brought similar information. There are two 
clinical applications for which these markers have been studied, 
namely the distinction of melanocytic naevi from SCMM and the 
assessment of clinical prognosis for patients with SCMM.
The most widely used proliferation marker is Ki67, a nuclear 
antigen present in all active phases of cell cycle proliferation (G1, 
S, G2 and M), but absent in the quiescent phase (G0) [34]. Ki67 
immunolabeling has been shown to be positive in <5% of cells in most 
melanocytic nevi. Up to 15% positivity may be found in cutaneous 
melanocytomas [35,36]. The quantitative loss of Ki67 expression with 
depth correlates with maturation and less atypical lesions [12,37]. A 
brisk mitotic rate or Ki67 index is not a common feature of cutaneous 
melanocytomas, but rather suggests SCMM. Most thin SCMM appear 
to be in a growth-stunted phase exhibiting an accretive rather than 
proliferative formation of nests. Thicker SCMM and their metastases 
have a higher Ki67 index. On the overall, the Ki67 index reaches 15-
30% of SCMM cells although some individual cases show much more 
nuclear positivity. The Ki67 index alone is not a reliable discriminator 
between SCMM and cutaneous melanocytomas when it ranges in the 
overlap 10-20%. The presence of SCMM stem cells (low Ki67 index) 
[38] and clonal events [39] further complicate the process [40].
In our experience, the Ki67 index of keratinocytes is often higher 
than that of tumoral cells in cutaneous melanocytomas. The reverse 
situation is seen in SCMM thicker than 0.4 mm.
Apoptosis is different from necrotic cell death and represents 
one major mechanism involved in reducing the expansible growth 
of melanocytic neoplasms. As a functional counterpart of mitosis, 
apoptosis plays a crucial role and is normally firmly regulated. 
Apoptosis is deranged in melanocytic neoplasms when the 
components and regulators of the cellular apoptotic machinery are 
mutated or present in inappropriate amounts. The pro-apoptotic 
factors include among others Bax, Bid, Fas/FasL, IFN, c-Kit/SCF, 
Noxa, p53, PITSLRE, PUMA, TNF and TRAIL. The anti-apoptotic 
factors include Bcl-2, Bcl-XI, livin, Mcl-1, ML-LAP, NFkB and 
survivin. Alternatively, other molecules including endothelins, 
integrins, c-Myc and TRAF-2 show either pro- or anti-apoptotic 
effects [41].
Apoptosis commonly appear quite active in cutaneous 
melanocytomas. The so-called Kamino bodies in Spitz melanocytoma 
likely result from such a process. At present the complex machinery 
of apoptosis has not been thoroughly studied in cutaneous 
melanocytomas.
Microvasculature of cutaneous melanocytomas
In thin MM, the microvascular density shows a wide range 
of development among distinct lesions. An overall stochastic 
relationship appears to be present between the microvasculature size 
and the size of the germinative compartment.
Microvessels have been reported to be fewer in cutaneous 
melanocytomas than in SCMM. The vascular endothelial growth 
factor (VEGF) is frequently detectable in SCMM, contrasting with 
the usual negativity in cutaneous melanocytomas.
The extent of angiogenesis may help in distinguishing cutaneous 
melanocytomas from SCMM. However, it should be noted that some 
growth-stunted SCMM show weak angiogenesis [42]. Conversely, 
angiomatoid cutaneous melanocytomas have been described [43]. 
Therefore, the differences in SCMM and cutaneous melanocytoma 
angiogenesis seem to be more statistically significant than clinically 
useful due to the extensive overlap in extent from any case to case.
Conclusion
Melanocytic neoplasms of the skin are heterogeneous in nature 
and in aspect. A vast number of genetic changes are described in 
SCMM, but the primary ones are not clearly defined. Cutaneous 
melanocytomas represent benign melanocytic neoplasms showing 
atypical features at the histological inspection. However, there is no 
single criterion defining cutaneous melanocytomas. The distinction 
between malignant melanoma and cutaneous melanocytomas is of 
utmost importance for the management of patients. The combination 
of moderately increased cell proliferation and heterogeneous patchy 
differentiation is a clue for cutaneous melanocytomas irrespective of 
their type. Most cutaneous melanocytomas appear to result from the 
effect of some internal or extrinsic triggering factors.
Traditional classification systems for SCMM have centered on 
clinicopathological correlations. Although some particular SCMM 
subtypes are clinically and histologically distinct, a wealth of studies 
indicates that current parameters for classification are without 
independent prognostic value. Indeed, some markers of potential 
clinical utility looking promising in small-scale studies fail to prove 
clinically useful in larger-scale studies. Such disappointing features 
appear to stem from the heterogeneous nature of SCMM during its 
evolution. A vast number of molecular changes are indeed present 
in advanced SCMM compared with melanocytes. Various mutations 
are disclosed from comparative gene expression profiling of SCMM 
from different stages. It is difficult to sort out which are central to 
malignancy and typical for SCMM. In the wide range of molecular 
changes it is therefore difficult to sharply define when a given 
melanocytic neoplasm becomes malignant. In this context, cutaneous 
melanocytomas are part of an evolving paradigm for classifying 
melanocytic neoplasms.
Cutaneous melanocytomas form an intermediate category 
of melanocytic neoplasms between common naevi and SCMM. 
They behave as benign lesions but their histological presentations 
may be troublesome or worrying. Immunohistochemistry 
evaluating differentiation markers and proliferation markers 
helps distinguishing cutaneous melanocytomas from SCMM. A 
multipronged immunohistochemical analysis should be performed 
in order to reach a high level of diagnostic accuracy.
We underscore recent studies that have provided insights into 
the diversity of melanocytic neoplasms. We expect these studies and 
subsequent analogous studies will inform the melanoma research 
community and the dermatologist as well in novel ways to manage 
patients with atypical melanocytic neoplasms.
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